Clinical applications of TNF-alpha in cancer

Curr Opin Immunol. 1998 Oct;10(5):573-80. doi: 10.1016/s0952-7915(98)80226-4.

Abstract

High-dose TNF-alpha plus chemotherapy, with or without IFN-gamma, can be safely administered regionally through isolated limb perfusion. This procedure produced between 70% and 80% complete remission in cases of in transit melanoma metastases and between 25% and 36% complete remission in cases of inextirpable soft-tissue sarcomas. Dual targeting is involved; TNF-alpha and IFN-gamma induce apoptosis of angiogenic endothelium, while melphalan induces apoptosis of tumour cells.

Publication types

  • Review

MeSH terms

  • Chemotherapy, Cancer, Regional Perfusion*
  • Dose-Response Relationship, Drug
  • Endothelium, Vascular / physiology
  • Humans
  • Interferon-gamma / physiology
  • Melanoma / therapy
  • Neoplasms / blood supply
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Neovascularization, Pathologic / prevention & control
  • Sarcoma / therapy
  • Tumor Necrosis Factor-alpha / administration & dosage*

Substances

  • Tumor Necrosis Factor-alpha
  • Interferon-gamma